Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 51
Filter
2.
Ann Intern Med ; 177(5): JC51, 2024 May.
Article in English | MEDLINE | ID: mdl-38710079

ABSTRACT

SOURCE CITATION: Giamarellos-Bourboulis EJ, Siampanos A, Bolanou A, et al. Clarithromycin for early anti-inflammatory responses in community-acquired pneumonia in Greece (ACCESS): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2024;12:294-304. 38184008.


Subject(s)
Anti-Bacterial Agents , Clarithromycin , Community-Acquired Infections , Humans , Clarithromycin/administration & dosage , Clarithromycin/therapeutic use , Community-Acquired Infections/drug therapy , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/therapeutic use , Double-Blind Method , Administration, Oral , Pneumonia/drug therapy , Male , Female , Pneumonia, Bacterial/drug therapy , Middle Aged , Drug Therapy, Combination
3.
Ann Intern Med ; 176(6): JC64, 2023 06.
Article in English | MEDLINE | ID: mdl-37276602

ABSTRACT

SOURCE CITATION: Paton NI, Cousins C, Suresh C, et al; TRUNCATE-TB Trial Team. Treatment strategy for rifampin-susceptible tuberculosis. N Engl J Med. 2023;388:873-887. 36808186.


Subject(s)
Antitubercular Agents , Tuberculosis , Humans , Antitubercular Agents/therapeutic use , Tuberculosis/drug therapy , Rifampin/therapeutic use , Drug Therapy, Combination
4.
Ann Intern Med ; 175(12): JC143, 2022 12.
Article in English | MEDLINE | ID: mdl-36469928

ABSTRACT

SOURCE CITATION: Thornhill MH, Gibson TB, Yoon F, et al. Antibiotic prophylaxis against infective endocarditis before invasive dental procedures. J Am Coll Cardiol. 2022;80:1029-41. 35987887.


Subject(s)
Endocarditis, Bacterial , Endocarditis , Adult , Humans , Antibiotic Prophylaxis , Dentistry
5.
Ann Intern Med ; 175(4): JC40, 2022 04.
Article in English | MEDLINE | ID: mdl-35377719

ABSTRACT

SOURCE CITATION: Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N Engl J Med. 2022;386:509-20. 34914868.


Subject(s)
COVID-19 , Adult , Cytidine/analogs & derivatives , Hospitalization , Humans , Hydroxylamines/adverse effects , SARS-CoV-2
6.
Pediatr Surg Int ; 38(3): 365-375, 2022 Mar.
Article in English | MEDLINE | ID: mdl-35006367

ABSTRACT

PURPOSE: The optimal age for minimally invasive repair of pectus excavatum (MIRPE) is unclear; this study investigates the differences in complication rates among different age groups undergoing repair. METHODS: PubMed and Embase databases were searched from inception to October 2020. To assess age as a risk factor for complications, odds ratios from relevant studies were analyzed using the Mantel-Haenszel method with a random-effects model for younger vs older patients. Specific complication rates were compared between the two cohorts using a chi-squared test. RESULTS: Of the 4448 studies retrieved, 25 studies stratified complication data by age groups. From these studies, ten studies compared groups at ages < 18 and ≥ 18 and four studies compared ages < 20 and ≥ 20, and one study compared ages < 19 and ≥ 19. These fifteen studies reported on 5978 patients, with 1188 complications, for a complication rate of 19.87%. Older patients were more likely to have complications in a pooled analysis of studies comparing older vs younger patients (OR = 1.66, 95% CI = 1.28-2.14, heterogeneity I2 = 49%). Specifically, older patients were significantly more likely to experience pneumothorax, pleural effusion, wound infection, bar displacement, and reoperations. CONCLUSION: Increased age is a risk factor for complications of MIRPE. This supports repair of pectus excavatum prior to late adolescence.


Subject(s)
Funnel Chest , Thoracoplasty , Adolescent , Funnel Chest/epidemiology , Funnel Chest/surgery , Humans , Minimally Invasive Surgical Procedures , Postoperative Complications/epidemiology , Reoperation , Retrospective Studies , Risk Factors , Treatment Outcome
7.
Am J Ind Med ; 65(2): 117-131, 2022 02.
Article in English | MEDLINE | ID: mdl-34825393

ABSTRACT

BACKGROUND: The World Trade Center (WTC) general responder cohort (GRC) was exposed to environmental toxins possibly associated with increased risk of developing autoimmune conditions. OBJECTIVES: Two study designs were used to assess incidence and risks of autoimmune conditions in the GRC. METHODS: Three clinically trained professionals established the status of possible GRC cases of autoimmune disorders adhering to diagnostic criteria, supplemented, as needed, by specialists' review of consenting responders' medical records. Nested case-control analyses using conditional logistic regression estimated the risk associated with high WTC exposure (being in the 9/11/2001 dust cloud or ≥median days' response worked) compared with low WTC exposure (all other GRC members'). Four controls were matched to each case on age at case diagnosis (±2 years), sex, race/ethnicity, and year of program enrollment. Sex-specific and sensitivity analyses were performed. GRC age- and sex-adjusted standardized incidence ratios (SIRs) were compared with the Rochester Epidemiology Project (REP). Complete REP inpatient and outpatient medical records were reviewed by specialists. Conditions meeting standardized criteria on ≥2 visits were classified as REP confirmed cases. RESULTS: Six hundred and twenty-eight responders were diagnosed with autoimmune conditions between 2002 and 2017. In the nested case-control analyses, high WTC exposure was not associated with autoimmune domains and conditions (rheumatologic domain odds ratio [OR] = 1.03, 95% confidence interval [CI] = 0.77, 1.37; rheumatoid arthritis OR = 1.12, 95% CI = 0.70, 1.77). GRC members had lower SIR than REP. Women's risks were generally greater than men's. CONCLUSIONS: The study found no statistically significant increased risk of autoimmune conditions with WTC exposures.


Subject(s)
Autoimmune Diseases , Emergency Responders , Occupational Exposure , September 11 Terrorist Attacks , Autoimmune Diseases/epidemiology , Case-Control Studies , Female , Humans , Incidence , Male , New York City , Occupational Exposure/adverse effects
8.
Ann Intern Med ; 174(11): JC124, 2021 11.
Article in English | MEDLINE | ID: mdl-34724399

ABSTRACT

SOURCE CITATION: Heath PT, Galiza EP, Baxter DN, et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N Engl J Med. 2021;385:1172-83. 34192426.


Subject(s)
COVID-19 , Vaccines , COVID-19 Vaccines , Humans , SARS-CoV-2
9.
Ann Intern Med ; 174(7): JC75, 2021 07.
Article in English | MEDLINE | ID: mdl-34224270

ABSTRACT

SOURCE CITATION: Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021. [Epub ahead of print.] 33882225.


Subject(s)
COVID-19 , Vaccines , COVID-19 Vaccines , Humans , SARS-CoV-2
10.
Ann Intern Med ; 173(8): JC47, 2020 10 20.
Article in English | MEDLINE | ID: mdl-33075255

ABSTRACT

SOURCE CITATION: Riccò M, Ferraro P, Gualerzi G, et al. Point-of-care diagnostic tests for detecting SARS-CoV-2 antibodies: a systematic review and meta-analysis of real-world data. J Clin Med. 2020;9:1515. 32443459.

12.
JNCI Cancer Spectr ; 4(1): pkz090, 2020 Feb.
Article in English | MEDLINE | ID: mdl-32337498

ABSTRACT

BACKGROUND: Following the September 11, 2001, attacks on the World Trade Center (WTC), thousands of workers were exposed to an array of toxins known to cause adverse health effects, including cancer. This study evaluates cancer incidence in the WTC Health Program General Responder Cohort occurring within 12 years post exposure. METHODS: The study population consisted of 28 729 members of the General Responder Cohort enrolled from cohort inception, July 2002 to December 31, 2013. Standardized incidence ratios (SIRs) were calculated with cancer case inclusion and follow-up starting post September 11, 2001 (unrestricted) and, alternatively, to account for selection bias, with case inclusion and follow-up starting 6 months after enrollment in the WTC Health Program (restricted). Case ascertainment was based on linkage with six state cancer registries. Under the restricted criterion, hazard ratios were estimated using multivariable Cox proportional hazards models for all cancer sites combined and for prostate cancer. RESULTS: Restricted analyses identified 1072 cancers in 999 responders, with elevations in cancer incidence for all cancer sites combined (SIR = 1.09, 95% confidence interval [CI] = 1.02 to 1.16), prostate cancer (SIR = 1.25, 95% CI = 1.11 to 1.40), thyroid cancer (SIR = 2.19, 95% CI = 1.71 to 2.75), and leukemia (SIR = 1.41, 95% CI = 1.01 to 1.92). Cancer incidence was not associated with any WTC exposure index (composite or individual) for all cancer sites combined or for prostate cancer. CONCLUSION: Our analyses show statistically significant elevations in cancer incidence for all cancer sites combined and for prostate and thyroid cancers and leukemia. Multivariable analyses show no association with magnitude or type of exposure.

14.
Am J Bioeth ; 19(6): 19-21, 2019 06.
Article in English | MEDLINE | ID: mdl-31135317
17.
Clin Infect Dis ; 66(1): 20-28, 2018 01 06.
Article in English | MEDLINE | ID: mdl-29020200

ABSTRACT

Background: The objective of this study was to assess differences in hepatitis C virus (HCV) incidence by sex in people who inject drugs (PWID), using a large international multicohort set of pooled biological and behavioral data from prospective observational studies of incident human immunodeficiency virus (HIV) and HCV infections in high-risk cohorts (the InC3 Collaborative). Methods: HCV infection date was estimated based on a hierarchy of successive serological (anti-HCV), virological (HCV RNA), and clinical (symptoms and/or liver function tests) data. We used a Cox proportional hazards model to calculate the crude and adjusted female to male (F:M) hazard ratio (HR) for HCV incidence using biological sex as the main exposure. Results: A total of 1868 PWID were observed over 3994 person-years of observation (PYO). Unadjusted F:M HR was 1.38 (95% confidence interval [CI], 1.15-1.65) and remained significant after adjusting for behavioral and demographic risk factors (1.39 [95% CI, 1.12-1.72]). Although syringe and equipment sharing were associated with the highest HCV incidence rate in women (41.62 and 36.83 PYO, respectively), we found no sex differences attributed to these risk factors. Conclusions: Our findings indicate that women who inject drugs may be at greater risk of HCV acquisition than men, independent of demographic characteristics and risk behaviors. Multiple factors, including biological (hormonal), social network, and differential access to prevention services, may contribute to increased HCV susceptibility in women who inject drugs.


Subject(s)
Hepatitis C/epidemiology , Sex Factors , Substance Abuse, Intravenous/complications , Adult , Female , Humans , Incidence , Male , Prospective Studies , Risk Factors
SELECTION OF CITATIONS
SEARCH DETAIL